<!DOCTYPE html>

<html lang="fa">
<meta content="text/html;charset=utf-8" http-equiv="content-type"/>
<head><title>Atropine and pralidoxime: Drug information</title><link href="/d/css/bootstrap.min.css" rel="stylesheet"/><link href="/d/css/icofont.min.css" rel="stylesheet"/><link href="/d/css/classy-nav.min.css" rel="stylesheet"/><link href="/d/css/animate.css" rel="stylesheet"/><link href="/d/css/owl.carousel.css" rel="stylesheet"/><link href="/d/css/magnific-popup.css" rel="stylesheet"/><link href="/d/css/owl.theme.default.min.css" rel="stylesheet"/><link href="/d/css/style.css" rel="stylesheet"/><link href="/d/css/rtl_edited.css" rel="stylesheet"/><link href="/d/css/responsive.css" rel="stylesheet"/><link href="https://medilib.ir/uptodate_assets/main.css" rel="stylesheet">
<style>

#myUL {
  list-style-type: none;
  padding: 0;
  margin: 0;
}

#myUL li a {
  border: 1px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #f6f6f6;
  padding: 12px;
  text-decoration: none;
  font-size: 16px;
  color: black;
  display: block
}

#myUL li a:hover:not(.header) {
  background-color: #eee;
}

#searchResult {

  list-style-type: none;
  padding: 0;
  padding-right: 20px;
}

#searchResult li a {
  border: .5px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #79bc21;
  padding: 7px;
  text-decoration: none;
  font-size: 14px;
  color: white;
  display: block
}

#searchResult li a:hover:not(.header) {
  background-color: #222;
}


#txtHint   {
  position: absolute;
  text-shadow: none;
  width: 100%;
  margin-top: -15px;
  padding-right: 10px;

  filter: alpha(opacity=95);
  -moz-opacity: 0.95;
  opacity: 1;
  z-index: 200;
}
.countBubl {
  background:#eb0029;
  color:#fff;
  padding:5px;
  margin-top: 50%;

}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(2) {
 width: 55%;
 padding-left: 20px;
}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(3) {
 width: 20%;
}
 #Uptodate_image {
      width: 50%;
  }#uptodate-area {
      /*z-index: 99;*/
  }
#uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > div:nth-child(2) {
 margin-left: 10px;
 margin-bottom: 6%;
}
@media (max-width: @screen-xs) {
    .countBubl {
        font-size: 4px ;
    }
    #uptodate_version {
        font-size: 4px ;
    }
}

@media (max-width: @screen-sm) {
    .countBubl {
        font-size: 14px ;
    }
}
@media  all and(max-width: 820) {
    #Uptodate_image {
        width: 80% ;
    }#uptodate-area {
        z-index: 99;
    }
}@media  all and (min-width: 820) and(max-width: 88820){
    #Uptodate_image {
        width: 100% !important;
    }
    .countBubl {
        font-size: 4px ;
    }
}
div.col-md-3:nth-child(3) {
 margin-top: 6%;
}

div.col-md-3:nth-child(3) > img:nth-child(1) {
 width: 100%;
 margin-left: 11px;
}

</style>
<style media="screen" type="text/css">
  .goback {
    width: 200px;
    height: 40px;
    line-height: 40px;
    position: fixed;
    display: none;
    font-size: 15px;
    background: #71c0fa;
    z-index: 1000;
    text-align: center;
    color: #ffffff;
    -webkit-border-radius: 1px;
    -moz-border-radius: 1px;
    border-radius: 50px;
    bottom: 3.8%;
    right: 2%;
}
  .buyPackage {
  width: 100px;
  height: 100px;
  line-height: 40px;
  position: fixed;
  display: none;
  font-size: 10px;
  background: #fa759e;
  z-index: 1000;
  text-align: center;
  color: #ffffff;
  -webkit-border-radius: 1px;
  -moz-border-radius: 1px;
  border-radius: 10px;
  top: 150px;
  right: 2%;
  text-align: center;
}
.uptodate-area {
  /*background-image: url(../../assets/img/news-letter-bg.jpg);*/
  background-position: center center;
  background-size: cover;
  background-repeat: no-repeat;
    background-attachment: fixed;
  position: relative;
}
.uptodate-area::before {
  content: '';
  position: absolute;
  left: 0;
  padding-top: 100px;
  width: 100%;
}
#references{
  display: none;
}
</style>
<style>
section.sticky {
  position: sticky;
  top: 0;
  background-color: #fff !important;
  /*z-index: 100;*/
  /*padding-top: 80px;*/

}
.m4inb{
    border: solid !important;
  }

  .newsletter-area::before {
       background: unset !important;
  }
p {
    color: #555;
}
</style>

<meta content="" name="description"/>
<link href="/d/img/favicon.png" rel="icon" type="image/png"/>
</link></head>
<body>
<!-- Start Main Menu Area -->

<br/>
<br/>
<br/>
<br/>
<div class="container">
<div class="row">
</div>
</div>




<section class="teacher-area ptb-10">
<div class="container">
</div>

<section class="course-details-area ptb-60">
<div class="container">
<div class="uptodate2" style="padding:50px 0px 50px 0px;direction: ltr;text-align: left;">
<h1 style="text-align:center">Atropine and pralidoxime: Drug information</h1>
<div class="utdArticleSection utdStyle" id="topicContent"><div id="drugTitle">Atropine and pralidoxime: Drug information</div><div class="clear"></div><div id="topicText">(For additional information <a class="drug drug_patient" data-topicid="11992" href="/d/html/11992.html" rel="external">see "Atropine and pralidoxime: Patient drug information"</a> and <a class="drug drug_pediatric" data-topicid="116889" href="/d/html/116889.html" rel="external">see "Atropine and pralidoxime: Pediatric drug information"</a>)<br/><br/>For abbreviations, symbols, and age group definitions used in Lexicomp (<a class="graphic graphic_table" href="/d/html/57469.html" rel="external">show table</a>)<div class="visuallyHidden drugH1Div" id="formulinkBodyPlaceholder"><span class="drugH1"></span></div>
<div class="list ubnlist drugH1Div drugBrandNames" id="F4302652"><span class="drugH1">Brand Names: US</span>
<ul>
<li>ATNAA;</li>
<li>Duodote [DSC]</li></ul></div>
<div class="ex_sect_xr thclist drugH1Div drugBrandNames" id="F4302656"><span class="drugH1">Pharmacologic Category</span>
<ul>
<li>
                        Anticholinergic Agent;</li>
<li>
                        Antidote</li></ul></div>
<div class="block doa drugH1Div" id="F4302682"><span class="drugH1">Dosing: Adult</span>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="8f71fa9f-003a-4776-8b7a-ef5b3150fc5f">Organophosphate insecticide or nerve agent poisoning</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Organophosphate insecticide or nerve agent poisoning:</b> IM: <b>Note:</b> If exposure is suspected, antidotal therapy should be given immediately as soon as symptoms appear (critical to administer immediately in case of soman exposure since its adverse effects develop within minutes). Definitive medical care should be sought after any injection given. One injection only may be given as self-aid. If repeat injections are needed, administration must be done by another trained individual. Emergency medical personnel who have self-administered a dose must determine their capacity to continue to provide care.</p>
<p style="text-indent:-2em;margin-left:2em;margin-top:2em;">
<b>ATNAA:</b></p>
<p style="text-indent:-2em;margin-left:4em;">Mild symptoms (some or all mild symptoms): Self-Aid or Buddy-Aid: 1 injection (wait 10 to 15 minutes for effect); if the patient is able to ambulate, and knows who and where they are, then no further injections are needed. If symptoms are still present: Buddy-Aid: May repeat 1 to 2 more injections</p>
<p style="text-indent:-2em;margin-left:4em;">Severe symptoms (if most or all): Buddy-Aid: If no self-aid given, 3 injections in rapid succession; if 1 self-aid injection given, 2 injections in rapid succession</p>
<p style="text-indent:-2em;margin-left:4em;">Maximum cumulative dose: 3 injections</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Symptoms of organophosphate insecticide or nerve agent poisoning, as provided by manufacturer in the ATNAA product labeling to guide therapy: </i></p>
<p style="text-indent:-2em;margin-left:6em;">Mild symptoms: Breathing difficulties, chest tightness, coughing, difficulty in seeing, drooling, headache, localized sweating and muscular twitching, miosis, nausea (with or without vomiting), runny nose, stomach cramps, tachycardia (followed by bradycardia), wheezing</p>
<p style="text-indent:-2em;margin-left:6em;">Severe symptoms: Bradycardia, confused/strange behavior, convulsions, increased wheezing and breathing difficulties, involuntary urination/defecation, miosis (severe), muscular twitching/generalized weakness (severe), red/teary eyes, respiratory failure, unconsciousness, vomiting</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>DuoDote:</b></p>
<p style="text-indent:-2em;margin-left:4em;">Mild symptoms (≥2 mild symptoms): 1 injection (wait 10 to 15 minutes for effect); if after 10 to 15 minutes no severe symptoms emerge, no further injections are indicated; if any severe symptoms emerge at any point following initial injection, repeat dose by giving 2 additional injections in rapid succession. Transport to medical care facility.</p>
<p style="text-indent:-2em;margin-left:4em;">Severe symptoms (≥1 severe symptom): 3 injections in rapid succession. Transport to medical care facility.</p>
<p style="text-indent:-2em;margin-left:4em;">Maximum cumulative dose: 3 injections unless medical care support (eg, hospital, respiratory support) is available</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Symptoms of organophosphate insecticide or nerve agent poisoning, as provided by manufacturer in the DuoDote product labeling to guide therapy:</i></p>
<p style="text-indent:-2em;margin-left:6em;">Mild symptoms: Airway secretions increased, blurred vision, bradycardia, breathing difficulties, chest tightness, drooling, miosis, nausea, vomiting, runny nose, salivation, stomach cramps (acute onset), tachycardia, teary eyes, tremors/muscular twitching, wheezing/coughing</p>
<p style="text-indent:-2em;margin-left:6em;">Severe symptoms: Breathing difficulties (severe), confused/strange behavior, convulsions, copious secretions from lung or airway, involuntary urination/defecation, muscular twitching/generalized weakness (severe), unconsciousness</p></div>
</div>
<p style="text-indent:-2em;margin-left:2em;margin-top:2em;">
<b>Dosage adjustment for concomitant therapy: </b>Significant drug interactions exist, requiring dose/frequency adjustment or avoidance. Consult drug interactions database for more information.</p></div>
<div class="block dora drugH1Div" id="F50990584"><span class="drugH1">Dosing: Kidney Impairment: Adult</span>
<p style="text-indent:0em;display:inline">There are no specific dosage adjustments provided in the manufacturer's labeling. Use with caution; pralidoxime may cause decreased renal function.</p></div>
<div class="block doha drugH1Div" id="F50987949"><span class="drugH1">Dosing: Hepatic Impairment: Adult</span>
<p style="text-indent:0em;display:inline">There are no specific dosage adjustments provided in the manufacturer's labeling; use with caution in patients with severe impairment.</p></div>
<div class="block doe drugH1Div" id="F4302683"><span class="drugH1">Dosing: Older Adult</span>
<p style="text-indent:0em;display:inline">Refer to adult dosing.</p></div>
<div class="block dop drugH1Div" id="F51107941"><span class="drugH1">Dosing: Pediatric</span><p>(For additional information <a class="drug drug_pediatric" data-topicid="116889" href="/d/html/116889.html" rel="external">see "Atropine and pralidoxime: Pediatric drug information"</a>)</p>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="8f71fa9f-003a-4776-8b7a-ef5b3150fc5f">Organophosphate insecticide or nerve agent poisoning</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Organophosphate insecticide or nerve agent poisoning:</b>
<b>Note:</b> If exposure is known or suspected, antidotal therapy should be given immediately as soon as symptoms appear (critical to administer immediately in case of soman exposure since its adverse effects develop within minutes). Only health care providers who have had adequate training in the recognition and treatment of nerve agent or insecticide intoxication should administer.</p>
<p style="text-indent:-2em;margin-left:4em;">Children and Adolescents weighing &gt;41 kg: DuoDote (atropine 2.1 mg/pralidoxime 600 mg per autoinjector):</p>
<p style="text-indent:-2em;margin-left:6em;">Mild symptoms (≥2 mild symptoms): IM: 1 injection (wait 10 to 15 minutes for effect); if after 10 to 15 minutes no severe symptoms emerge, no further injections are indicated; if any severe symptoms emerge at any point following initial injection, repeat dose by giving 2 additional injections in rapid succession. Transport to medical care facility.</p>
<p style="text-indent:-2em;margin-left:6em;">Severe symptoms (≥1 severe symptom): IM: 3 injections in rapid succession. Transport to medical care facility.</p>
<p style="text-indent:-2em;margin-left:6em;">Maximum cumulative dose: 3 injections unless medical care support (eg, hospital, respiratory support) is available</p>
<p style="text-indent:-2em;margin-left:6em;">
<i>Symptoms of organophosphate insecticide or nerve agent poisoning, as provided by manufacturer in the DuoDote product labeling to guide therapy:</i></p>
<p style="text-indent:-2em;margin-left:8em;">Mild symptoms: Airway secretions increased, blurred vision, bradycardia, breathing difficulties, chest tightness, drooling, miosis, nausea, vomiting, runny nose, salivation, stomach cramps (acute onset), tachycardia, teary eyes, tremors/muscular twitching, wheezing/coughing</p>
<p style="text-indent:-2em;margin-left:8em;">Severe symptoms: Breathing difficulties (severe), confused/strange behavior, convulsions, copious secretions from lung or airway, involuntary urination/defecation, muscular twitching/generalized weakness (severe), unconsciousness</p></div>
</div>
<p style="text-indent:-2em;margin-left:2em;">
<b>Dosage adjustment for concomitant therapy:</b> Significant drug interactions exist, requiring dose/frequency adjustment or avoidance. Consult drug interactions database for more information.</p></div>
<div class="block dorp drugH1Div" id="F51257806"><span class="drugH1">Dosing: Kidney Impairment: Pediatric</span>
<p style="text-indent:0em;display:inline">There are no dosage adjustments provided in the manufacturer's labeling. Use with caution; pralidoxime can cause kidney impairment.</p></div>
<div class="block dohp drugH1Div" id="F51257807"><span class="drugH1">Dosing: Hepatic Impairment: Pediatric</span>
<p style="text-indent:0em;display:inline">There are no dosage adjustments provided in manufacturer's labeling. Use with caution in severe impairment.</p></div>
<div class="block adr drugH1Div" id="F4302667"><span class="drugH1">Adverse Reactions</span>
<p style="text-indent:0em;display:inline">The following adverse drug reactions and incidences are derived from product labeling unless otherwise specified.</p>
<p style="text-indent:-2em;margin-left:2em;">Frequency not defined. Reactions reported with Duodote. Also see individual agents.</p>
<p style="text-indent:-2em;margin-left:2em;">Cardiovascular: Transient increase of blood pressure (usually occurring 15 minutes after administration and returning to baseline 4 hours post-dose)</p>
<p style="text-indent:-2em;margin-left:2em;">Central nervous system: Hypertonia (at injection site; mild-to-moderate)</p>
<p style="text-indent:-2em;margin-left:2em;">Local: Pain at injection site (mild-to-moderate)</p></div>
<div class="block coi drugH1Div" id="F4302663"><span class="drugH1">Contraindications</span>
<p style="text-indent:0em;display:inline">No contraindications exist in the treatment of life-threatening organophosphate insecticide or nerve agent poisoning</p></div>
<div class="block war drugH1Div" id="F4302664"><span class="drugH1">Warnings/Precautions</span>
<p style="text-indent:-2em;margin-left:2em;">
<b>
<i>Concerns related to adverse effects:</i></b></p>
<p style="text-indent:-2em;margin-left:4em;">• Atropinization: Signs of atropinization (eg, flushing, mydriasis, tachycardia, dryness of mouth or nose) may occur earlier than expected with the use of a combination product as compared to atropine alone. Monitor effects closely when administering subsequent injections as necessary. The presence of these effects is not indicative of the success of therapy. Reversal of bronchial secretions is the preferred indicator of success.</p>
<p style="text-indent:-2em;margin-left:4em;">• Hyperthermia: Atropine may inhibit sweating and possibly lead to heat-related injury or hyperthermia in patients exposed to warm environments or exercise.</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>
<i>Disease-related concerns:</i></b> The following diseases are relative precautions only when symptoms of poisoning are <b>not</b> severe:</p>
<p style="text-indent:-2em;margin-left:4em;">• Cardiovascular disease: Use with caution in patients with heart disease, arrhythmias (eg, atrial flutter), severe CAD, or history of recent MI; treatment-related blood pressure increases and tachycardia may lead to ischemia, precipitate an MI, or increase arrhythmogenic potential.</p>
<p style="text-indent:-2em;margin-left:4em;">• Chronic lung disease: Use with caution in patients with chronic lung disease; may cause inspiration of bronchial secretions and formation of dangerous viscid plugs.</p>
<p style="text-indent:-2em;margin-left:4em;">• Hepatic impairment: Use with caution in patients with hepatic impairment; effects of atropine may be prolonged in severe hepatic impairment.</p>
<p style="text-indent:-2em;margin-left:4em;">• Myasthenia gravis: Use with caution in patients with myasthenia gravis; may precipitate myasthenic crisis.</p>
<p style="text-indent:-2em;margin-left:4em;">• Narrow-angle glaucoma: Use with caution in patients with severe narrow-angle glaucoma; may precipitate acute glaucoma.</p>
<p style="text-indent:-2em;margin-left:4em;">• Pyloric stenosis: Use with caution in patients with pyloric stenosis; may cause complete pyloric obstruction.</p>
<p style="text-indent:-2em;margin-left:4em;">• Renal impairment: Use with caution in renal impairment; pralidoxime is excreted renally and the effects of atropine may be prolonged in severe renal impairment.</p>
<p style="text-indent:-2em;margin-left:4em;">• Urinary obstruction: Use with caution in patients with urinary obstruction; may cause urinary retention.</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>
<i>Special populations:</i></b></p>
<p style="text-indent:-2em;margin-left:4em;">• Older adult: May be more sensitive to the anticholinergic effects of atropine.</p>
<p style="text-indent:-2em;margin-left:4em;">• Pediatric: May be more sensitive to the anticholinergic effects of atropine.</p>
<p style="text-indent:-2em;margin-left:2em;">
<i>
<b>Dosage form specific issues: </b></i></p>
<p style="text-indent:-2em;margin-left:4em;">• Benzyl alcohol and derivatives: Some dosage forms may contain sodium benzoate/benzoic acid; benzoic acid (benzoate) is a metabolite of benzyl alcohol; large amounts of benzyl alcohol (≥99 mg/kg/day) have been associated with a potentially fatal toxicity (“gasping syndrome”) in neonates; the “gasping syndrome” consists of metabolic acidosis, respiratory distress, gasping respirations, CNS dysfunction (including convulsions, intracranial hemorrhage), hypotension, and cardiovascular collapse (AAP ["Inactive" 1997]; CDC 1982); some data suggests that benzoate displaces bilirubin from protein binding sites (Ahlfors 2001); avoid or use dosage forms containing benzyl alcohol derivative with caution in neonates. See manufacturer's labeling.</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>
<i>Other warnings/precautions:</i></b></p>
<p style="text-indent:-2em;margin-left:4em;">• Appropriate use: Clinical symptoms consistent with highly-suspected organophosphate insecticide or nerve agent poisoning should be treated with antidote immediately; administration should not be delayed for confirmatory laboratory tests. Treatment should always include proper evacuation and decontamination procedures; medical personnel should protect themselves from inadvertent contamination. Antidotal administration is intended only for initial management; definitive and more extensive medical care is required following administration. Individuals should not rely solely on antidote for treatment, as other supportive measures (eg, artificial respiration) may still be required. Continued administration of additional doses in asymptomatic patients may result in atropine toxicity.</p></div>
<div class="block add-pediatric-warn-info drugH1Div" id="F52878711"><span class="drugH1">Warnings: Additional Pediatric Considerations</span>
<p style="text-indent:0em;display:inline">CNS effects (eg, restlessness, tremor, fatigue, locomotor difficulties, delirium, hallucinations) of atropine are often seen earlier and at lower doses in pediatric patients compared to adults.</p></div>
<div class="block foc drugH1Div" id="F4302689"><span class="drugH1">Dosage Forms: US</span>
<p style="text-indent:0em;display:inline">Excipient information presented when available (limited, particularly for generics); consult specific product labeling.</p>
<p style="text-indent:-2em;margin-left:2em;">Injection, solution:</p>
<p style="text-indent:-2em;margin-left:4em;">ATNAA, Duodote [DSC]: Atropine 2.1 mg/0.7 mL and pralidoxime chloride 600 mg/2 mL [contains benzyl alcohol; prefilled autoinjector]</p></div>
<div class="block geq drugH1Div" id="F4302654"><span class="drugH1">Generic Equivalent Available: US</span>
<p style="text-indent:0em;display:inline">No</p></div>
<div class="block fee drugH1Div" id="F16324114"><span class="drugH1">Pricing: US</span>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">
<b>Solution Auto-injector</b> (DuoDote Intramuscular)</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">2.1-600 mg (per mL): $22.58</p>
<p style="text-indent:0em;">
<b>Disclaimer: </b>A representative AWP (Average Wholesale Price) price or price range is provided as reference price only. A range is provided when more than one manufacturer's AWP price is available and uses the low and high price reported by the manufacturers to determine the range. The pricing data should be used for benchmarking purposes only, and as such should not be used alone to set or adjudicate any prices for reimbursement or purchasing functions or considered to be an exact price for a single product and/or manufacturer.  Medi-Span expressly disclaims all warranties of any kind or nature, whether express or implied, and assumes no liability with respect to accuracy of price or price range data published in its solutions.  In no event shall Medi-Span be liable for special, indirect, incidental, or consequential damages arising from use of price or price range data.  Pricing data is updated monthly.</p></div>
<div class="block accres drugH1Div" id="F11217266"><span class="drugH1">Prescribing and Access Restrictions</span>
<p style="text-indent:-2em;margin-left:2em;">ATNAA (<b>A</b>ntidote <b>T</b>reatment-<b>N</b>erve <b>A</b>gent <b>A</b>uto-Injector) is only available for use by US Armed Forces military personnel. Information on distribution is available at Defense Services Supply Center-Philadelphia at 215-737-2341.</p>
<p style="text-indent:-2em;margin-left:2em;">Duodote is only available for use by trained emergency medical services personnel to treat civilians. Distribution is limited to directly from manufacturer (Meridian Medical Technologies, Inc) to emergency medical service organizations or their suppliers.</p></div>
<div class="block adm drugH1Div" id="F4302685"><span class="drugH1">Administration: Adult</span>
<p style="text-indent:0em;margin-left:0em;display:inline">IM:</p>
<p style="text-indent:-2em;margin-left:2em;">ATNAA: May be administered in the lateral thigh muscle or buttocks. The first dose may be self-administered; subsequent doses must be administered by a buddy. Remove the gray safety cap from the back end; place the front end on the outer thigh or buttocks and push hard to activate the injector. Hold firmly in place for 10 seconds. After use, bend the needle into a hook shape against a hard surface.</p>
<p style="text-indent:-2em;margin-left:2em;">DuoDote: Self-administration: Hold the device firmly at the center with the green tip (needle end) pointing down; remove the gray safety release with the other hand. Do not touch the green tip at any time. Removal of clothing is not necessary, but pockets should be empty. Firmly push green tip straight down (90° angle) against the mid-lateral thigh. Hold firmly in place until auto-injector triggers and for ~10 seconds after device has triggered. After administration, the needle will be visible; if the needle is not visible, repeat the above steps. After use, bend the needle against a hard surface (needle does not retract) to avoid accidental injury.</p></div>
<div class="block admp drugH1Div" id="F52614232"><span class="drugH1">Administration: Pediatric</span>
<p style="text-indent:0em;display:inline">IM:</p>
<p style="text-indent:-2em;margin-left:2em;">DuoDote: Administer IM into the mid-lateral thigh. Hold the device firmly at the center with the green tip (needle end) pointing down; remove the gray safety release with the other hand; do not touch the green tip at any time. The device is now ready for administration into the mid-lateral thigh; removal of clothing is not necessary, but pockets should be empty. If patient does not have a lot of fat at the injection site, bunch up thigh tissue for a thicker injection area. Firmly push the green tip against the mid-lateral thigh. Hold firmly in place until auto-injector triggers and continue to hold for 10 seconds after the device has triggered. The needle does not retract; after administration, the needle should be visible; if the needle is not visible, repeat the above steps. After use, bend the needle against a hard surface to avoid accidental injury.</p></div>
<div class="block use drugH1Div" id="F4303276"><span class="drugH1">Use: Labeled Indications</span>
<p style="text-indent:-2em;margin-left:2em;">
<b>Organophosphate insecticide or nerve agent poisoning: </b></p>
<p style="text-indent:-2em;margin-left:4em;">ATNAA: Treatment of poisoning in patients who have been exposed to organophosphate nerve agents (eg, sarin, soman, tabun, VX) that have acetylcholinesterase-inhibiting activity for self- or buddy-administration by military personnel</p>
<p style="text-indent:-2em;margin-left:4em;">DuoDote: Treatment of poisoning by organophosphate nerve agents (eg, sarin, soman, tabun, VX) or organophosphate insecticides in adult and pediatric patients weighing &gt;41 kg for use by trained emergency medical services personnel</p></div>
<div class="block cyt drugH1Div" id="F13298795"><span class="drugH1">Metabolism/Transport Effects</span>
<p style="text-indent:0em;display:inline">None known.</p></div>
<div class="block dri drugH1Div" id="F4302671"><span class="drugH1">Drug Interactions</span><br/><br/><div class="clear"></div><p xmlns=""></p><div class="inner" xmlns=""><p style="text-indent:0em;display:inline"><b>Note</b>: Interacting drugs may <b>not be individually listed below</b> if they are part of a group interaction (eg, individual drugs within “CYP3A4 Inducers [Strong]” are NOT listed).  For a complete list of drug interactions by individual drug name and detailed management recommendations, use the Lexicomp drug interactions program by clicking on the “Launch drug interactions program” link above.</p><p xmlns=""></p></div>
<p style="text-indent:-2em;margin-left:2em;">Acetylcholinesterase Inhibitors: May diminish the therapeutic effect of Anticholinergic Agents. Anticholinergic Agents may diminish the therapeutic effect of Acetylcholinesterase Inhibitors.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Aclidinium: May enhance the anticholinergic effect of Anticholinergic Agents.<i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Alpha1-Agonists: Atropine (Systemic) may enhance the hypertensive effect of Alpha1-Agonists. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Amantadine: May enhance the anticholinergic effect of Anticholinergic Agents.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Amezinium: Atropine (Systemic) may enhance the stimulatory effect of Amezinium. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Anticholinergic Agents: May enhance the adverse/toxic effect of other Anticholinergic Agents.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Botulinum Toxin-Containing Products: May enhance the anticholinergic effect of Anticholinergic Agents.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Cannabinoid-Containing Products: Anticholinergic Agents may enhance the tachycardic effect of Cannabinoid-Containing Products. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Chloral Betaine: May enhance the adverse/toxic effect of Anticholinergic Agents.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Chlorprothixene: Anticholinergic Agents may enhance the anticholinergic effect of Chlorprothixene. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Cimetropium: Anticholinergic Agents may enhance the anticholinergic effect of Cimetropium. <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">CloZAPine: Anticholinergic Agents may enhance the constipating effect of CloZAPine.  Management: Consider alternatives to this combination whenever possible. If combined, monitor closely for signs and symptoms of gastrointestinal hypomotility and consider prophylactic laxative treatment.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Eluxadoline: Anticholinergic Agents may enhance the constipating effect of Eluxadoline. <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">EPHEDrine (Systemic): Atropine (Systemic) may enhance the therapeutic effect of EPHEDrine (Systemic). <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Gastrointestinal Agents (Prokinetic): Anticholinergic Agents may diminish the therapeutic effect of Gastrointestinal Agents (Prokinetic). <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Glucagon: Anticholinergic Agents may enhance the adverse/toxic effect of Glucagon. Specifically, the risk of gastrointestinal adverse effects may be increased. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Glycopyrrolate (Oral Inhalation): Anticholinergic Agents may enhance the anticholinergic effect of Glycopyrrolate (Oral Inhalation). <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Glycopyrronium (Topical): May enhance the anticholinergic effect of Anticholinergic Agents.<i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Ipratropium (Oral Inhalation): May enhance the anticholinergic effect of Anticholinergic Agents.<i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Itopride: Anticholinergic Agents may diminish the therapeutic effect of Itopride. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Levosulpiride: Anticholinergic Agents may diminish the therapeutic effect of Levosulpiride. <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Macimorelin: Atropine (Systemic) may diminish the diagnostic effect of Macimorelin. <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Mianserin: May enhance the anticholinergic effect of Anticholinergic Agents.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Mirabegron: Anticholinergic Agents may enhance the adverse/toxic effect of Mirabegron. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Nitroglycerin: Anticholinergic Agents may decrease the absorption of Nitroglycerin. Specifically, anticholinergic agents may decrease the dissolution of sublingual nitroglycerin tablets, possibly impairing or slowing nitroglycerin absorption. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Opioid Agonists: Anticholinergic Agents may enhance the adverse/toxic effect of Opioid Agonists. Specifically, the risk for constipation and urinary retention may be increased with this combination. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Oxatomide: May enhance the anticholinergic effect of Anticholinergic Agents.<i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Potassium Chloride: Anticholinergic Agents may enhance the ulcerogenic effect of Potassium Chloride.  Management: Patients on drugs with substantial anticholinergic effects should avoid using any solid oral dosage form of potassium chloride.<i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Potassium Citrate: Anticholinergic Agents may enhance the ulcerogenic effect of Potassium Citrate.  Management:  Patients on drugs with substantial anticholinergic effects should avoid using any solid oral dosage form of potassium citrate.<i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Pramlintide: May enhance the anticholinergic effect of Anticholinergic Agents. These effects are specific to the GI tract.<i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Ramosetron: Anticholinergic Agents may enhance the constipating effect of Ramosetron. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Revefenacin: Anticholinergic Agents may enhance the anticholinergic effect of Revefenacin. <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Ritodrine: Atropine (Systemic) may enhance the adverse/toxic effect of Ritodrine. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Rivastigmine: Anticholinergic Agents may diminish the therapeutic effect of Rivastigmine. Rivastigmine may diminish the therapeutic effect of Anticholinergic Agents.  Management: Use of rivastigmine with an anticholinergic agent is not recommended unless clinically necessary. If the combination is necessary, monitor for reduced anticholinergic effects.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Secretin: Anticholinergic Agents may diminish the therapeutic effect of Secretin.  Management: Avoid concomitant use of anticholinergic agents and secretin. Discontinue anticholinergic agents at least 5 half-lives prior to administration of secretin.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Sincalide: Drugs that Affect Gallbladder Function may diminish the therapeutic effect of Sincalide.  Management: Consider discontinuing drugs that may affect gallbladder motility prior to the use of sincalide to stimulate gallbladder contraction.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Thiazide and Thiazide-Like Diuretics: Anticholinergic Agents may increase the serum concentration of Thiazide and Thiazide-Like Diuretics. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Tiotropium: Anticholinergic Agents may enhance the anticholinergic effect of Tiotropium. <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Topiramate: Anticholinergic Agents may enhance the adverse/toxic effect of Topiramate. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Umeclidinium: May enhance the anticholinergic effect of Anticholinergic Agents.<i> Risk X: Avoid combination</i></p></div>
<div class="block pri drugH1Div" id="F4302659"><span class="drugH1">Pregnancy Considerations</span>
<p style="text-indent:0em;">Atropine crosses the placenta.</p>
<p style="text-indent:0em;margin-top:2em;">Information related to the use of atropine/pralidoxime following organophosphate poisoning in pregnant patients is limited (Bailey 2003; Kamha 2005; Sun 2015). In general, medications used as antidotes should take into consideration the health and prognosis of the mother; antidotes should be administered to pregnant women if there is a clear indication for use and should not be withheld because of fears of teratogenicity (Bailey 2003).</p>
<p style="text-indent:0em;margin-top:2em;">Refer to individual monographs for additional information.</p></div>
<div class="block brc drugH1Div" id="F4302662"><span class="drugH1">Breastfeeding Considerations</span>
<p style="text-indent:-2em;margin-left:2em;">Atropine is present in breast milk; excretion of pralidoxime is not known.</p>
<p style="text-indent:-2em;margin-left:2em;margin-top:0em;">According to the manufacturer, the decision to breastfeed following therapy should consider the risk of infant exposure, the benefits of breastfeeding to the infant, and the benefits of treatment to the mother.</p>
<p style="text-indent:-2em;margin-left:2em;margin-top:0em;">Refer to individual monographs for additional information.</p></div>
<div class="block mop drugH1Div" id="F4302687"><span class="drugH1">Monitoring Parameters</span>
<p style="text-indent:0em;display:inline">Respiratory status, ABGs, pulse oximeter; body temperature (especially in warm climates); blood pressure (peak effect occurs ~15 minutes after administration); symptoms of poisoning</p></div>
<div class="block rer drugH1Div" id="F4302677"><span class="drugH1">Reference Range</span>
<p style="text-indent:0em;display:inline">Direct measurement of RBC acetylcholinesterase activity provides a measure of degree of toxicity, although symptoms may not correlate with the degree of inactivation unless activity is reduced to &lt;50%. Sequential measurement (if rapidly available) may help to determine the effectiveness of pralidoxime therapy. Plasma (or pseudo) cholinesterase activity is more easily performed, but does not correlate well with the severity and should not be used to guide therapy.</p></div>
<div class="block pha drugH1Div" id="F4302675"><span class="drugH1">Mechanism of Action</span>
<p style="text-indent:0em;">Atropine: Functions as a competitive antagonist of acetylcholine at muscarinic receptors in the peripheral and central nervous system, thus reducing the symptoms of parasympathetic overstimulation resulting from excess acetylcholine caused by organophosphate insecticide or nerve agent poisoning. The parasympatholytic action of atropine decreases oral and respiratory secretions, relieves airway constriction, and attenuates the bradycardia induced by organophosphate insecticides and nerve agents. Antagonizes acetylcholine accumulation at respiratory center and may reduce centrally-mediated respiratory paralysis. </p>
<p style="text-indent:0em;margin-top:2em;">Pralidoxime: An oxime which functions by way of nucleophilic attack on the ester site of the acetylcholinesterase enzyme which has been deactivated by phosphorylation. Displacement of the phosphoryl group allows reactivation of acetylcholinesterase’s hydrolytic activity, thus permitting renewed catalysis of accumulated acetylcholine. Destruction of accumulated acetylcholine allows for restoration of normal functioning at neuromuscular junctions and relief from respiratory muscle paralysis. </p></div>
<div class="block phk drugH1Div" id="F4302678"><span class="drugH1">Pharmacokinetics (Adult Data Unless Noted)</span>
<p style="text-indent:0em;display:inline">See individual agents.</p></div>
</div><div class="headingAnchor" id="references"><ol id="reference">
<li>
<div class="reference" id="lexi-content-ref-11487763">
<a name="11487763"></a>Ahlfors CE. Benzyl alcohol, kernicterus, and unbound bilirubin. <i>J Pediatr</i>. 2001;139(2):317-319. doi: 10.1067/mpd.2001.116281.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/atropine-and-pralidoxime-drug-information/abstract-text/11487763/pubmed" id="11487763" target="_blank">11487763</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-ATNAA.1">
<a name="ATNAA.1"></a>ATNAA (atropine and pralidoxime) [prescribing information]. St. Louis, MO: Meridian Medical Technologies LLC; July 2022.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-25672327">
<a name="25672327"></a>Broach J, Krupa R, Bird SB, Manuell ME. Regional preparedness for mass acetylcholinesterase inhibitor poisoning through plans for stockpiling and interhospital sharing of pralidoxime. <i>Am J Disaster Med.</i> 2014;9(4):237-245.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/atropine-and-pralidoxime-drug-information/abstract-text/25672327/pubmed" id="25672327" target="_blank">25672327</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-6810084">
<a name="6810084"></a>Centers for Disease Control (CDC). Neonatal deaths associated with use of benzyl alcohol—United States. <i>MMWR Morb Mortal Wkly Rep</i>. 1982;31(22):290-291. <a href="https://www.cdc.gov/mmwr/preview/mmwrhtml/00001109.htm" target="_blank">http://www.cdc.gov/mmwr/preview/mmwrhtml/00001109.htm</a>.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/atropine-and-pralidoxime-drug-information/abstract-text/6810084/pubmed" id="6810084" target="_blank">6810084</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-DuoDote.1">
<a name="DuoDote.1"></a>DuoDote (atropine and pralidoxime) [prescribing information]. St. Louis, MO: Meridian Medical Technologies LLC; June 2022.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-9024461">
<a name="9024461"></a>"Inactive" ingredients in pharmaceutical products: update (subject review). American Academy of Pediatrics (AAP) Committee on Drugs. <i>Pediatrics</i>. 1997;99(2):268-278.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/atropine-and-pralidoxime-drug-information/abstract-text/9024461/pubmed" id="9024461" target="_blank">9024461</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-15853933">
<a name="15853933"></a>Kamha AA, Al Omary IY, Zalabany HA, Hanssens Y, Adheir FS. Organophosphate poisoning in pregnancy: a case report. <i>Basic Clin Pharmacol Toxicol</i>. 2005;96(5):397‐398. doi:10.1111/j.1742-7843.2005.pto_09.x<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/atropine-and-pralidoxime-drug-information/abstract-text/15853933/pubmed" id="15853933" target="_blank">15853933</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-27170033">
<a name="27170033"></a>Khan SR, Mohammad A, Khan MA, Faustino PJ. Critical importance and quality evaluation of drug delivery autoinjectors in the FDA-DOD Shelf Life Extension Program (SLEP). <i>AAPS J</i>. 2016;18(4):801-803.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/atropine-and-pralidoxime-drug-information/abstract-text/27170033/pubmed" id="27170033" target="_blank">27170033</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-12394966">
<a name="12394966"></a>Leikin JB, Thomas RG, Walter FG, et al, “A Review of Nerve Agent Exposure for the Critical Care Physician,” <i>Crit Care Med</i>, 2002, 30(10):2346-54.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/atropine-and-pralidoxime-drug-information/abstract-text/12394966/pubmed" id="12394966" target="_blank">12394966</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-18514464">
<a name="18514464"></a>Rebmann T, Clements BW, Bailey JA, et al, "Organophosphate Antidote Auto-Injectors vs Traditional Administration: A Time Motion Study," <i>J Emerg Med</i>, 2009, 37(2):139-43.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/atropine-and-pralidoxime-drug-information/abstract-text/18514464/pubmed" id="18514464" target="_blank">18514464</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-19773481">
<a name="19773481"></a>Sandilands EA, Good AM, and Bateman DN, "The Use of Atropine in a Nerve Agent Response with Specific Reference to Children: Are Current Guidelines Too Cautious?" <i>Emerg Med J</i>, 2009, 26(10):690-4.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/atropine-and-pralidoxime-drug-information/abstract-text/19773481/pubmed" id="19773481" target="_blank">19773481</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Sidell.1997">
<a name="Sidell.1997"></a>Sidell FR, Takafuji ET, Franz DR, eds. <i>Medical Aspects of Chemical and Biological Warfare: Textbook of Military Medicine. Part 1, Warfare, Weaponry, and the Casualty</i>. Office of the Surgeon General, Department of the Army, USA; 1997.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-25542453">
<a name="25542453"></a>Sun L, Li GQ, Yan PB, Liu Y, Li GF, Wei LQ. Clinical management of organophosphate poisoning in pregnancy. <i>Am J Emerg Med</i>. 2015;33(2):305.e1‐305.e3053. doi:10.1016/j.ajem.2014.05.057<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/atropine-and-pralidoxime-drug-information/abstract-text/25542453/pubmed" id="25542453" target="_blank">25542453</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-USAMRICD.2020">
<a name="USAMRICD.2020"></a>US Army Medical Research Institute of Chemical Defense (USAMRICD). Nerve agents. In: <i>Medical Management of Chemical Casualties Handbook</i>. 3rd ed. 2000;56-74.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-HHS.2021">
<a name="HHS.2021"></a>US Department of Health and Human Services (USDHHS). Nerve agent treatment-autoinjector instructions. <a href="https://chemm.hhs.gov/antidote_nerveagents.htm" target="_blank">https://chemm.hhs.gov/antidote_nerveagents.htm</a>. Updated August 16, 2021. Accessed January 31, 2022.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-15845747">
<a name="15845747"></a>Weinbroum AA, “Pathophysiological and Clinical Aspects of Combat Anticholinesterase Poisoning,” <i>Brit Med Bulletin</i>, 2005, 72:119-33.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/atropine-and-pralidoxime-drug-information/abstract-text/15845747/pubmed" id="15845747" target="_blank">15845747</a>]</span>
</div>
</li></ol></div><div id="topicVersionRevision">Topic 9441 Version 204.0</div></div>
</div>
</div>

</section>

</section>
<!-- End Main Menu Area -->
<!-- Start Search Popup Area -->


<!-- End Footer Area -->
<!-- Back to top -->

<a class="scrolltop" href="#top"><i class="icofont-hand-drawn-up"></i></a>
<!-- End Back to top -->
<!-- jQuery Min JS -->

<!-- Prpper JS -->

<!-- Bootstrap Min JS -->

<!-- Classy Nav Min Js -->

<!-- Owl Carousel Min Js -->

<!-- Magnific Popup JS -->

<!-- CounterUp JS -->

<!-- Waypoints JS -->

<!-- Form Validator Min JS -->

<!-- Contact Form Min JS -->

<!-- Main JS -->

<!-- Global site tag (gtag.js) - Google Analytics -->






</body>
</html>
